# Advaccine Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advaccine-biotech

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.advaccine.com
- Total disclosed funding: $29M
- Latest round: Series C (Jan 6, 2025)
- Investors on record: 11

## About

Based in Suzhou, China, and established in 2009, Advaccine Biotech is a biotechnology company that focuses on vaccine production. The company has merged with SA Biotech (Suzhou) Pte Ltd and established a large-scale vaccine production system in Suzhou. In December 2020, the initiation of phase II clinical trial of pGX9501 was started. Xian Zhu, the founder and president of the company, has served as Executive Vice President, Chief Scientific Officer, and Chief Biologics Officer for multinational companies such as Fidelity Animal Health, Pfizer Animal Health, etc. In January 2025, Advaccine Biotech closed a series C+ funding.

Advaccine Biotech engages in the development and production of new preventive vaccines and therapeutic vaccines, which can prevent and treat diseases caused by excessive immune responses. The vaccine production of the company includes innovative vaccine technologies such as DNA nucleic acid vaccines, recombinant protein vaccines, and new vaccine adjuvants. It is developing COVID-19 DNA vaccine, new respiratory syncytial virus (RSV) pneumonia vaccine, hepatitis B therapeutic vaccine, etc.

The company generates revenue by developing pet vaccines.

## Funding rounds

- Series C, Jan 6, 2025 — KGI Asia, Changshu Guofa Venture Capital, Fosun Health Capital
- Series C, Feb 20, 2024 — SND Ventures Group, Sealand Innovation, Star Capital, GSR United Capital, Shanghai Songqing Private Equity Fund Management
- Series B, Sep 30, 2020, $29M — New Alliance Capital, MPC, Star Capital
- Series A, Mar 31, 2017 — Fortune Capital, Star Capital

## Investors

- Fortune Capital — Series A
- Star Capital — Series A, Series B, Series C
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series B
- MPC — Series B
- SND Ventures Group (https://capitalatlas.ai/funds/snd-ventures-group) — Series C
- Sealand Innovation (https://capitalatlas.ai/funds/sealand-innovation) — Series C
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Series C
- Shanghai Songqing Private Equity Fund Management — Series C
- KGI Asia — Series C
- Changshu Guofa Venture Capital (https://capitalatlas.ai/funds/changshu-guofa-venture-capital) — Series C
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series C